

Background

- Alcohol-associated liver disease (ALD) is the single most important driver of cirrhosis and liver cancer-related deaths over the past decade.¹
- Despite ALD being an expensive and increasingly common condition², there is **low utilization** of alcohol use disorder (AUD) treatment in **hospitalized patients with ALD**.³
- Few studies have aimed to investigate barriers to implementing AUD interventions for hospitalized ALD patients.

Objective

 To assess current practices and barriers of linking hospitalized patients with alcohol-associated liver disease (ALD) to alcohol use disorder (AUD) treatment at UCLA

Methods

- **Study design:** qualitative; data collection method: in-person via video teleconferencing, semi-structured interviews, April 2021 – May 2021
- Setting: UCLA Ronald Reagan Medical Center
- **Participants:** *Providers* (N=17): healthcare professionals responsible for providing care to hospitalized patients with ALD
- **Interviews:** guides developed to explore the current process for connecting hospitalized patients with ALD to AUD care. Pilot tested in 2 individuals. Observational notes written after each interview.
- **Analysis:** transcribed audio-files; iterative analysis and discussions of observational notes

Role

Hepatologist

Hepatobiliary transplant surgeon

Advanced practice provide

Registered nurse

Social worker

Transplant coordinator

Psychiatrist

Pharmacist

David Geffen School of Medicine Current practices and barriers to alcohol use disorder treatment for hospitalized adults with clocked of the second s hospitalized adults with alcohol-associated liver disease Eric An PhD¹, Yun Wang MD¹, Arpan Patel MD PhD¹ ¹David Geffen School of Medicine at UCLA

Major Themes and Representative Quotes

	Providers (N=17)
	4 (23%)
	1 (6%)
er	3 (17%)
se	2 (12%)
	2 (12%)
	2 (12%)
	2 (12%)
	1 (6%)

Current practices

1. AUD treatment is limited to minimal participation in Alcoholics Anonymous (AA) in the hospital setting. "So, regarding the medications for addiction. I would just say that I think we probably do a pretty poor job at it. A very poor job at it, in fact." (LT Registered nurse)

"I don't know. I don't think much. Because the thing is that this is all in the inpatient setting. What else can we do? I don't even know. They say do your AA and that's like the only thing I feel like we can offer. I don't know what else we can." (LT Hepatologist)

2. There is limited support from addiction psychiatry services in the hospital setting.

"It's very difficult to get addiction psychiatry consultation...I don't know, for some reason, the psychiatry department here are very selective who they want to see and who's not." (LT Hepatologist)

Barriers

3. There is poor knowledge of best practices in addressing AUD. "No, no [we didn't get any addiction medicine training]. And I think that's probably one of the hesitancy of, "Do we treat?" 'cause it's a complex thing of addiction in itself, you know?" (LT Transplant **Coordinator**)

4. There is poor support for addiction follow up. Successful referral to addiction services is dependent on the patient's initiative.

"[Finding a psychiatrist through insurance] becomes the patient's responsibility, and that's another issue, too...I feel like, for me, because I always say – or if I try to put myself in this situation, for me, the bigger barrier would be just figuring it out." (LT Advanced **Practice Provider**)

5. There is a lack of shared understanding of what interventions need to be implemented based on patient factors. "I guess [who manages medications] depends on who's got the most active role. Either hepatologist or addiction medicine specialist or psychiatrist." (LT Hepatologist)

- to hospitalized patients with ALD.

- study. BMJ. 2018; 362: k2817.
- jamanetworkopen.2020.1997





Conclusions

• Identified themes reflect current deficits, specifically in delivering medical and psychological interventions for AUD, along with establishing AUD treatment referrals.

• There is low prioritization to integrate AUD treatment in inpatient settings due to multiple barriers.

Efforts are needed to improve delivery of AUD treatment

Limitations

 Given this was a qualitative study, the frequencies of behaviors (e.g., current practices) could not be measured.

• The practices and barriers in the medical center of this study may not be generalizable to other medical centers.

• We could not investigate all perspectives involved in addressing AUD care at this medical center (e.g., psychology; family medicine/addiction medicine).

References

1. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational

2. Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Netw Open. 2020;3(4):e201997.doi:10.1001/

3. Winters A, et al. Gaps in the quality of care delivered to hospitalized patients with alcohol-associated liver disease [abstract 239]. Hepatology 2020;72:131A-1159A